Lexicon Pharmaceuticals | LXRX - Zobowiązania Handlowe





Zobowiązania Handlowe Zmiana Data
Abbott USD 4.24B 117M 2025-12
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
Akebia Therapeutics USD 8.39M 12.8M 2026-03
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
AstraZeneca USD 22.51B 2.78B 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Coherus Biosciences USD 9.91M 14.98M 2025-12
Eli Lilly USD 5.03B 350M 2026-03
Esperion Therapeutics USD 68.41M 3.34M 2026-03
Halozyme Therapeutics USD 14.1M 6.8M 2026-03
Illumina USD 218M 22M 2026-03
Insmed USD 73.38M 6.53M 2026-03
Ironwood Pharmaceuticals USD 3.24M 339K 2026-03
J&J USD 10.46B 1.53B 2026-03
Lexicon Pharmaceuticals USD 3M 87K 2026-03
MacroGenics USD 4.29M 500K 2026-03
MannKind USD 16.14M 7.11M 2026-03
Merck USD 3.86B 541M 2026-03
Moderna USD 161M 156M 2026-03
Novartis USD 4.32B 134M 2026-03
PTC Therapeutics USD 25.48M 20M 2026-03
Puma Biotechnology USD 6.39M 962K 2025-09
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
Thermo Fisher Scientific USD 3.34B 278M 2026-03
Ultragenyx Pharmaceutical USD 42M 11M 2026-03
United Therapeutics USD 498.3M 491.2M 2026-03
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12